血管免疫母细胞性T细胞淋巴瘤12例临床分析

为了探讨血管免疫母细胞性T细胞淋巴瘤(AITL)的临床、病理特征及预后情况,回顾性分析了经病理检查证实的12例AITL患者的临床特点、病理形态及免疫表型、治疗和生存情况。结果表明:12例患者主要症状为全身淋巴结肿大,9例伴有发热等全身症状。确诊依据淋巴结活检,病理组织学呈现淋巴结结构破坏,免疫母细胞增生,树枝状血管增生的特点,免疫表型全部为成熟外周T细胞性。12例患者均用CVP为主的化疗方案,总有效率58%。3年生存率为25%,全组中位生存25个月。结论:AITL临床过程呈侵袭性,进展快,中位生存期短,预后差,应探索更为有效的治疗方案。

Clinical Analysis of 12 Patients with Angioimmunoblastic T Cell Lymphoma

To evaluate the clinical,pathological characters and prognosis of patients with angioimmunoblastic T cell lymphoma（AITL）,the clinicopathologic features,immunophenotypes,therapy and survival rate of 12 AITL patients which were confirmed by pathologic examination were retrospectively studied.The results indicated that main symptom was observed as general lymphadenopathy,however,9 patients had fever.The diagnosis of AITL was based on lymph-node biopsy.The histopathologic characteristics of AITL showed the damage of normal lymphonode structure,the proliferation of immunoblastic cells and arborescent supervascularization.All immunophenotypes were mature peripheral T-cellular.CVP regimen was the most common chemotherapy regimen used for patients.58% patients have a good initial response to chemotherapy.3-year survival was 25%,with median survival time of 25 months.In conclusion,most cases of AITL display an aggressive course,therefore,the disease progresses rapidly and has unfavorable prognosis,further studies are required to improve its therapy regimen.